Gilead Sciences Inc. named Andrew Dickinson its new CFO, replacing Robin Washington, effective Nov. 1.
Dickinson has been with the company since 2016 and is executive vice president, corporate development and strategy. He will continue with the role after he becomes CFO, Gilead said in an Oct. 15 release.
The executive led Gilead's 2017 acquisition of Kite Pharma Inc., and the $5.05 billion research collaboration with Galapagos NV that was announced in July, the company said. Dickinson served as global co-head of healthcare investment banking at Lazard Frères & Co. before joining Gilead.
Washington will remain with the company in an advisory capacity until early 2020 and will work with Dickinson during the transition.